Stockscreener 앱 받기
3.53
2.75%
-0.10
시간 외 거래:
3.53
Voyager Therapeutics Inc 주식(VYGR)의 최신 뉴스
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - markets.businessinsider.com
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading - Stock Titan
Voyager director granted options for 30,000 shares | VYGR Insider Trading - Stock Titan
Voyager Therapeutics (VYGR) director receives 30,000 stock options grant - Stock Titan
Voyager Therapeutics (VYGR) director granted 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options - Stock Titan
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote - Stock Titan
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation - Yahoo Finance
Guggenheim Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Voyager’s tau-targeted gene therapy VY-1706 gains IND approval - BioWorld News
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Gains FDA Approval for Alzheimer's G - GuruFocus
Voyager Therapeutics Receives FDA Clearance to Begin Clinical Trial of VY1706 Gene Therapy for Alzheimer’s Disease - Minichart
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease - markets.businessinsider.com
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy - TipRanks
Voyager Therapeutics receives FDA clearance to begin Alzheimer’s gene therapy trial - Investing.com India
FDA clears Voyager Therapeutics (VYGR) IND for Alzheimer’s gene therapy VY1706 - Stock Titan
Voyager Receives FDA IND Clearance for VY1706, First Gene - GlobeNewswire
Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window - Bez Kabli
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress - Investing.com Australia
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress By Investing.com - Investing.com South Africa
Voyager Therapeutics Q1 2026 Earnings: Narrower‑than‑Expected Loss Drives Positive Stock Reaction - The Legal Advocate
Voyager Therapeutics Inc. (VYGR) Q1 2026 Earnings: Narrowed Loss Meets Optimism in Gene Therapy PipelineEPS Consistency Score - Newser
Voyager Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseNet Income Trends - Newser
Voyager Therapeutics (VYGR) Shares Rebound 4.76% as Biotech Sector Shows StrengthCrowd Risk Alerts - Newser
- Insider Monkey
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings - Stock Titan
The one question every Voyager Therapeutics VYGR investor should ask Bullish Sentiment 20260510Weak Earnings Momentum - The Legal Advocate
VYGR (NASDAQ: VYGR) affiliate files Form 144 to sell 25,000 shares - Stock Titan
EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment - Stock Titan
Armistice Capital (VYGR) reports 3.5M shares, 5.87% stake in Voyager - Stock Titan
Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares - Stock Titan
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TradingKey - TradingKey
VYGR Technical Analysis | Trend, Signals & Chart Patterns | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill
Voyager presents preclinical data for Alzheimer’s gene therapy By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Reports Positive Findings for Alzhei - GuruFocus
VYGR Secures Mission Management Contract for ISS Research - GuruFocus
Voyager presents preclinical data for Alzheimer’s gene therapy - Investing.com UK
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 - The Manila Times
Voyager Therapeutics Advances VY1706 Gene Therapy for Alzheimer's Disease with IND Application on Track for Q2 2026 - Quiver Quantitative
1.27%
1.43%
자본화:
|
볼륨(24시간):